APA (7th ed.) Citation

Christopoulos, P., Bozorgmehr, F., Brückner, L., Chung, I., Krisam, J., Schneider, M. A., . . . Thomas, M. (2021, June). Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: Study protocol of the ABP trial. BMC Cancer.

Chicago Style (17th ed.) Citation

Christopoulos, Petros, et al. "Brigatinib Versus Other Second-generation ALK Inhibitors as Initial Treatment of Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer with Deep Phenotyping: Study Protocol of the ABP Trial." BMC Cancer Jun. 2021.

MLA (9th ed.) Citation

Christopoulos, Petros, et al. "Brigatinib Versus Other Second-generation ALK Inhibitors as Initial Treatment of Anaplastic Lymphoma Kinase Positive Non-small Cell Lung Cancer with Deep Phenotyping: Study Protocol of the ABP Trial." BMC Cancer, Jun. 2021.